BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22133292)

  • 1. The role of cyclin D1 expression and patient's survival in non-small-cell lung cancer: a systematic review with meta-analysis.
    Zhang LQ; Jiang F; Xu L; Wang J; Bai JL; Yin R; Wu YQ; Meng LJ
    Clin Lung Cancer; 2012 May; 13(3):188-95. PubMed ID: 22133292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of p16 in non-small cell lung cancer and its prognostic significance: a meta-analysis of published literatures.
    Tong J; Sun X; Cheng H; Zhao D; Ma J; Zhen Q; Cao Y; Zhu H; Bai J
    Lung Cancer; 2011 Nov; 74(2):155-63. PubMed ID: 21621871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced expression of cyclin D2 is associated with poor recurrence-free survival independent of cyclin D1 in stage III non-small cell lung cancer.
    Ko E; Kim Y; Park SE; Cho EY; Han J; Shim YM; Park J; Kim DH
    Lung Cancer; 2012 Aug; 77(2):401-6. PubMed ID: 22534667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of matrix metalloproteinase 9 expression in patients with non-small cell lung cancer.
    Peng WJ; Zhang JQ; Wang BX; Pan HF; Lu MM; Wang J
    Clin Chim Acta; 2012 Jul; 413(13-14):1121-6. PubMed ID: 22465234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationships between cyclin D1 expression and prognosis of non-small cell lung cancer.
    Zhu J; Yu L; Zhan P; Song Y; Wang Q
    Zhongguo Fei Ai Za Zhi; 2010 Aug; 13(8):803-8. PubMed ID: 20704822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression profile and clinic significance of the SIX family in non-small cell lung cancer.
    Liu Q; Li A; Tian Y; Liu Y; Li T; Zhang C; Wu JD; Han X; Wu K
    J Hematol Oncol; 2016 Nov; 9(1):119. PubMed ID: 27821176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of cyclin D1 and vascular endothelial growth factor(VEGF) in non-small cell lung carcinoma and their association with the prognosis].
    Liang RY; Liao ZS; Jiang SP; Zhang W; Li JG; Zheng DH
    Ai Zheng; 2003 Jan; 22(1):86-90. PubMed ID: 12561444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project.
    Berghmans T; Dusart M; Paesmans M; Hossein-Foucher C; Buvat I; Castaigne C; Scherpereel A; Mascaux C; Moreau M; Roelandts M; Alard S; Meert AP; Patz EF; Lafitte JJ; Sculier JP;
    J Thorac Oncol; 2008 Jan; 3(1):6-12. PubMed ID: 18166834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Impact of Tissue Inhibitor of Metalloproteinase-1 in Non- Small Cell Lung Cancer: Systematic Review and Meta-Analysis.
    Selvaraj G; Kaliamurthi S; Lin S; Gu K; Wei DQ
    Curr Med Chem; 2019; 26(42):7694-7713. PubMed ID: 30182835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of the apoptotic index analysed jointly with selected cell cycle regulators and proliferation markers in non-small cell lung cancer.
    Dworakowska D; Jassem E; Jassem J; Karmoliński A; Lapiński M; Tomaszewski D; Rzyman W; Jaśkiewicz K; Sworczak K; Grossman AB
    Lung Cancer; 2009 Oct; 66(1):127-33. PubMed ID: 19200616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of tissue inhibitor of metalloproteinase-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis.
    Zhu L; Yu H; Liu SY; Xiao XS; Dong WH; Chen YN; Xu W; Zhu T
    PLoS One; 2015; 10(4):e0124230. PubMed ID: 25905787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of angiopoietin-2 in non-small cell lung cancer patients: a meta-analysis.
    Xuan ZX; Zhang S; Yuan SJ; Wang W; Yu J
    World J Surg Oncol; 2016 Sep; 14(1):237. PubMed ID: 27589869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer.
    Xu YH; Lu S
    Eur J Surg Oncol; 2014 Mar; 40(3):311-7. PubMed ID: 24332948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating β-catenin signaling pathway.
    Wang Z; Luo Z; Zhou L; Li X; Jiang T; Fu E
    Cancer Sci; 2015 Oct; 106(10):1303-12. PubMed ID: 26212035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers.
    Nishio M; Koshikawa T; Yatabe Y; Kuroishi T; Suyama M; Nagatake M; Sugiura T; Ariyoshi Y; Mitsudomi T; Takahashi T
    Clin Cancer Res; 1997 Jul; 3(7):1051-8. PubMed ID: 9815783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of cyclin D1 overexpression in correlation with pRb and p53 status in non-small cell lung cancer (NSCLC).
    Dworakowska D; Jassem E; Jassem J; Boltze C; Wiedorn KH; Dworakowski R; Skokowski J; Jaśkiewicz K; Czestochowska E
    J Cancer Res Clin Oncol; 2005 Jul; 131(7):479-85. PubMed ID: 15809880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma.
    Tsai MF; Wang CC; Chang GC; Chen CY; Chen HY; Cheng CL; Yang YP; Wu CY; Shih FY; Liu CC; Lin HP; Jou YS; Lin SC; Lin CW; Chen WJ; Chan WK; Chen JJ; Yang PC
    J Natl Cancer Inst; 2006 Jun; 98(12):825-38. PubMed ID: 16788156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of pretreatment prognostic nutritional index in non-small cell lung cancer: A systematic review and meta-analysis.
    Hu Y; Shen J; Liu R; Feng Z; Zhang C; Ling L; Chen L
    Int J Biol Markers; 2018 Nov; 33(4):372-378. PubMed ID: 30282502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negative effect of cyclin D1 overexpression on recurrence-free survival in stage II-IIIA lung adenocarcinoma and its expression modulation by vorinostat in vitro.
    Lee E; Jin D; Lee BB; Kim Y; Han J; Shim YM; Kim DH
    BMC Cancer; 2015 Dec; 15():982. PubMed ID: 26681199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cox-2 in non-small cell lung cancer: a meta-analysis.
    Jiang H; Wang J; Zhao W
    Clin Chim Acta; 2013 Apr; 419():26-32. PubMed ID: 23384501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.